check_circleStudy Completed
Atrial Fibrillation
Bayer Identifier:
20030
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study to gather information about the safety of oral anticoagulation drugs and how well these drugs work in real world for patients with non-valvular atrial fibrillation (irregularly heart beats which is not caused by a heart valve problem)
Trial purpose
Oral anticoagulant (OAC) treatment with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) is essential in patients with atrial fibrillation for the prevention of stroke or systemic embolism (SE) a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel. While there are significant number of real-world publications on the use and outcomes of NOACs for stroke prevention, evidence from routine clinical practice on the use and outcomes of reduced doses of NOACs is scarce. By evaluating routine clinical practice data from national registers in Denmark, Finland, Norway and Sweden, researchers want to gather information about the safety and how well reduced doses of NOACs work in patients with irregularly heartbeats which are not caused by a heart valve problem (non-valvular atrial fibrillation, NVAF). As a primary aim of this study, treatment with low doses of NOACs (Xarelto [generic name rivaroxaban], Eliquis [generic name apixaban] or Pradaxa [generic name dabigatran]) will be compared with VKAs (warfarin) in Nordic patients with NVAF to assess the occurrence of stroke and systemic embolism [effectiveness]) and intracranial hemorrhage a type of bleeding that occurs inside the skull [safety]).
Key Participants Requirements
Sex
AllAge
18 - N/ATrial summary
Enrollment Goal
134897Trial Dates
March 2020 - September 2023Phase
N/ACould I Receive a placebo
NoProducts
Xarelto (Rivaroxaban, BAY59-7939)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many locations | Many locations, Sweden |
Primary Outcome
- Number of participants with ischemic stroke (IS) or systemic embolism (SE)Evaluation will be done in participants treated with reduced doses of individual NOACs and with VKAdate_rangeTime Frame:Retrospective analysis from 2010 - 2018
- Number of participants with intracranial haemorrhage (ICH)Evaluation will be done in participants treated with reduced doses of individual NOACs and with VKAdate_rangeTime Frame:Retrospective analysis from 2010 - 2018
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A